Next-Generation Bispecific Nanobody Targeting CD3 Complex and MUC16 for Advanced Cancer Immunotherapy
VHH-P598 is a humanized nanobody-based bispecific antibody fusion construct under active Biological Testing, designed to target both CD3 Complex (T Cell Receptor Complex) and mucin 16, cell surface associated (MUC16). By simultaneously engaging these two validated targets, VHH-P598 aims to mediate potent and selective immune cell redirection toward malignant cells expressing MUC16, a well-characterized cancer antigen. Leveraging a unique structure and dual-targeting approach, VHH-P598 offers significant potential as an innovative therapeutic modality for various cancers with high unmet medical needs.
| Candidate | VHH-P598 |
| Target | CD3 Complex (T Cell Receptor Complex) mucin 16, cell surface associated (MUC16) |
| Modality | humanized bispecific VHH |
| Indication | Cancer |
Licensing Opportunity
VHH-P598 is available for out-licensing and collaborative partnership opportunities. We welcome inquiries from biopharmaceutical companies and research organizations seeking to co-develop or access this innovative bispecific nanobody platform for oncology applications.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P598 |
Modality
VHH-P598 is a bispecific fusion construct consisting of a camelid-derived single-domain antibody targeting CD3, connected via a flexible (G4S)4 linker to a VHH specializing in MUC16, and fused to a human IgG1 Fc domain. This architecture is expressed in human embryonic kidney 293 cells, facilitating scalable production with human-compatible posttranslational modifications. Nanobody-based single-domain format confers compact molecular size, high tissue penetration, and superior stability relative to conventional antibodies. The modular fusion, along with Fc engineering, affords extended half-life and efficient immune effector function, optimizing its applicability for cancer therapy by increasing local tumor infiltration and immunogenic engagement.
Target
CD3 Complex and MUC16 are integral and distinct molecular targets for cancer therapy. CD3 Complex is a key component of the T cell receptor, orchestrating antigen-specific immune responses and predominantly expressed on T lymphocytes. MUC16 is an aberrantly overexpressed surface glycoprotein in several malignancies, serving as a hallmark of cancer cell phenotype. Targeting CD3 Complex brings cytotoxic T cells into proximity with cancer cells marked by MUC16, triggering cell-mediated cytolysis. The dual specificity of VHH-P598 maximizes the selectivity, reducing off-tumor effects. The strategic targeting of CD3 Complex and MUC16 positions this therapeutic for innovation in immune cell redirection therapies, addressing the heterogeneity and resistance seen in current oncology interventions.
Mechanism of Action
VHH-P598 operates as a bispecific T-cell engager by simultaneously binding CD3 Complex on T cells and MUC16 present on tumor cells. This dual-targeting mechanism physically juxtaposes cytotoxic T lymphocytes with malignant cells, catalyzing targeted immune synapse formation and tumor cell elimination through T-cell mediated cytotoxicity. As a signal transduction modulator, VHH-P598 triggers T-cell activation upon CD3 engagement only in the presence of MUC16-expressing cancer cells, minimizing off-target effects. The nanobody platform also opens possibilities for novel therapeutic formats including antibody-drug conjugates or multispecific constructs, further broadening potential clinical applications against diverse and challenging cancer types.
Cancer
Cancer remains the leading cause of global morbidity and mortality, comprising a broad spectrum of diseases characterized by uncontrolled cellular proliferation and capacity for tissue invasion and metastasis. Incidence is rising due to aging populations and environmental factors. Standard-of-care therapies such as surgery, chemotherapy, and radiation offer clinical benefit, but are often limited by toxicity, lack of specificity, and the emergence of resistance. Recent advances in immunotherapy and targeted treatments have transformed the landscape of cancer care; however, many patients experience suboptimal responses or relapse, indicating significant unmet needs, particularly for advanced or refractory disease. VHH-P598, by engaging CD3 Complex and MUC16 simultaneously, proposes a novel approach to potentiate T-cell mediated tumor clearance while minimizing off-target effects, offering promise for improved outcomes in cancers expressing MUC16 and beyond.